Contact SCGE
Your email
Message
Send
SCGE Consortium Home
About SCGE TCDC
Contact Us
License
Home
Gene Therapy Trial Browser
Clinical Trial Report
Gene Therapy Trial Report
Summary
4D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP)
NCTID
NCT04517149
(View at clinicaltrials.gov)
Description
This is a Phase 1/2 multicenter study with two parallel parts: an observational natural history cohort and an open-label, prospective interventional trial in males with non-syndromic X-linked retinitis pigmentosa (XLRP) due to mutations in the gene encoding retinitis pigmentosa GTPase regulator (RPGR).
(Show More)
Development Status
Inactive
Indication
X-Linked Retinitis Pigmentosa
Disease Ontology Term
DOID:0110414
Compound Name
4D-125
Sponsor
4D Molecular Therapeutics
Funder Type
Industry
Recruitment Status
Active not recruiting
Enrollment Count
21
Results Posted
Not Available
Therapy Information
Target Gene/Variant
RPGR
Therapy Type
Gene transfer
Therapy Route
In-vivo
Mechanism of Action
Functional gene replacement
Route of Administration
Intravitreal
Drug Product Type
Viral vector
Target Tissue/Cell
Delivery System
Viral transduction
Vector Type
AAV
Editor Type
none
Dose 1
3E11 vg/eye
Dose 2
1E12 vg/eye
Dose 3
Dose 4
Dose 5
Study Record Dates
Current Stage
Phase1, Phase2
Submit Date
2020-08-14
Completion Date
2029-05
Last Update
2025-03-21
Participation Criteria
Eligible Age
>=12 Years
Standard Ages
Child, Adult, Older adult
Sexes Eligible for Study
MALE
Locations
No.of Trial Sites
8
Locations
United States
Regulatory Information
Has US IND
True
FDA Designations
Fast Track, Orphan Drug Designation
Recent Updates
January 2025: Sponsor announced they would terminate development of this program
Resources/Links
News and Press Releases
SEC Form 10-Q: 4D Molecular Therapeutics, Inc. Q3 2024
Interim Results, October 10, 2021
4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway